Tech Track 100

Based on research into embryonic stem cells in mice by chief scientific officer Allan Bradley, 60, Kymab has developed antibodies with the potential to protect us from some of the world’s most life-threatening autoimmune diseases, cancer and even Covid-19. Kymab was spun out of The Wellcome Trust Sanger Institute in 2009 and has raised $280m from investors, including the Bill & Melinda Gates Foundation, with which it is currently collaborating to test a number of potential Covid-19 vaccines. The Cambridge firm increased revenues to £8.7m last year, after new chief executive Simon Sturge, 61, joined in May. It is said to be considering a float.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2020
Rank87
CompanyKymab
ActivityBiopharmaceuticals developer
LocationCambridge
Average 3 year sales growth52.81%
Latest sales £000s8,671
Staff183
Founded2009
Websitewww.kymab.com

If applicable:

* supplied by company † annualised figure